Partner Therapeutics Strengthens Oncology Portfolio With BIZENGRI
LEXINGTON, Mass., May 11, 2026 Partner Therapeutics, Inc. (PTx) announced that the U.S. Food and Drug Administration (FDA) has...
oncology biologics
Advertisement
Partner Therapeutics Files sBLA for BIZENGRI in CCA
LEXINGTON, MASSACHUSETTS, USA, April 14, 2026 Partner Therapeutics, Inc. has announced the submission of a supplemental Biologics License Application...
Henlius Secures NMPA IND for HLX319 Breast Cancer Drug
SHANGHAI, China, April 1, 2026 Shanghai Henlius Biotech, Inc. announced that the China National Medical Products Administration (NMPA) has...
CanWell Pharma Secures FDA IND for CAN016 ADC Trial
WOBURN, Mass., April 1, 2026 CanWell Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
MiNK Therapeutics Highlights Phase II iNKT Therapy at AACR
NEW YORK, April 3, 2026 MiNK Therapeutics announced that new Phase II clinical trial data for its investigational iNKT...
Advertisements
FDA Approves DARZALEX FASPRO Quadruplet for NDMM Care
HORSHAM, PENNSYLVANIA | January 27, 2026 — Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA)...
Advertisement
